Aclaris Therapeutics, Inc.
ACRS
$1.52
$0.0251.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.78M | 18.72M | 27.08M | 32.02M | 31.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.78M | 18.72M | 27.08M | 32.02M | 31.12M |
| Cost of Revenue | 50.46M | 49.04M | 61.57M | 85.28M | 101.48M |
| Gross Profit | -32.68M | -30.32M | -34.49M | -53.26M | -70.36M |
| SG&A Expenses | 21.50M | 22.20M | 24.56M | 26.00M | 29.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.96M | 71.25M | 86.14M | 111.28M | 131.04M |
| Operating Income | -54.18M | -52.53M | -59.06M | -79.26M | -99.92M |
| Income Before Tax | -130.21M | -132.07M | -37.37M | -59.05M | -77.63M |
| Income Tax Expenses | -- | -- | -367.00K | -367.00K | -367.00K |
| Earnings from Continuing Operations | -130.21 | -132.07 | -37.00 | -58.68 | -77.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.21M | -132.07M | -37.00M | -58.68M | -77.26M |
| EBIT | -54.18M | -52.53M | -59.06M | -79.26M | -99.92M |
| EBITDA | -53.99M | -52.22M | -58.66M | -78.83M | -99.42M |
| EPS Basic | -1.40 | -1.51 | -0.52 | -0.83 | -1.09 |
| Normalized Basic EPS | -0.30 | -0.35 | -0.44 | -0.62 | -0.80 |
| EPS Diluted | -1.40 | -1.51 | -0.52 | -0.83 | -1.09 |
| Normalized Diluted EPS | -0.30 | -0.35 | -0.44 | -0.62 | -0.80 |
| Average Basic Shares Outstanding | 360.37M | 309.05M | 284.61M | 284.04M | 283.38M |
| Average Diluted Shares Outstanding | 360.37M | 309.05M | 284.61M | 284.04M | 283.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |